December 2021 -

Presentation at the 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022): Propella Therapeutics Corporate Presentation

Propella Therapeutics, Inc. participated in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022.

Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event

Propella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer.

Presentation at the MedInvest Oncology Conference (December 7-10, 2021): Propella Therapeutics Corporate Presentation

Propella Therapeutics, Inc. presented at the MedInvest Oncology Conference on December 7, 2021.